Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death

American Journal of Psychiatry

Volumn 158, Issue 11, 2001, Pages 1774-1782

  Glassman, A H ^a   Bigger J T , Jr ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CETIRIZINE; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; KETOCONAZOLE; MESORIDAZINE; MESORIDAZINE BESYLATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PIMOZIDE; POTASSIUM CHANNEL; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; TERFENADINE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

AGRANULOCYTOSIS; DOSE RESPONSE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SUDDEN DEATH; TORSADE DES POINTES;

ANTIPSYCHOTIC AGENTS; DEATH, SUDDEN; FEMALE; HUMANS; LONG QT SYNDROME; MALE; SCHIZOPHRENIA; TORSADES DE POINTES;

EID: 0035150202     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.11.1774     Document Type: Review

References (67)

1. Safety concerns over antipsychotic drug, sertindole
2. Physicians' desk reference
3. Ventricular tachycardia with two variable opposing foci
4. Ventricular fibrillation and twisted peaks
5. The QT interval and torsade de pointes
6. Torsades de pointes occurring in association with terfenadine use
7. Assessing the cardiac safety of ebastine: Prologue
8. Mechanism of the cardiotoxic actions of terfenadine
9. Risk of torsades de pointes with non-cardiac drugs
10. Torsade de pointes
11. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review
12. Prolonged QT interval predicts cardiac and allcause mortality in the elderly: The Rotterdam study
13. Correct the QT interval correctly: QTc should be expressed in the same unit as the QT interval
14. Second-generation antihistamines: The risk of ventricular arrhythmias
15. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current
16. Thioridazine hydrochloride (Mellaril): Its effects on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities
17. Five cases of pigmentary retinopathy associated with thioridazine administration
18. Pigmentary retinopathy associated with thioridazine administration
19. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs
20. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: A review
21. Tricyclic antidepressants in depressed patients with cardiac conduction disease
22. The safety of tricyclic antidepressants in cardiac patients: Risk-benefit reconsidered
23. Case study: Two additional sudden deaths with tricyclic antidepressants
24. Cardiovascular effects of tricyclic antidepressants
25. Sudden death as a risk of neuroleptic treatment (a continuing controversy)
26. American psychiatric association task force report 27: Sudden death in psychiatric patients - The role of neuroleptic drugs
27. Cardiovascular side effects of phenothiazines and tricyclic antidepressants: A review
28. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 Cases in Finland
29. Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings
30. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia
31. Cardiovascular adverse effects of antipsychotic drugs
32. Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes
33. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome
34. Arrhythmogenic effects of sultopride chlorhydrate: Clinical and cellular electrophysiological correlation
35. Electrocardiographic changes in patients receiving neuroleptic medication
36. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol (letter)
37. Haloperidol-induced torsades de pointes
38. The association between intravenous haloperidol and torsades de pointes: Three cases and a literature review
39. Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose
40. Torsades de pointes associated with intravenous haloperidol in critically ill patients
41. Sertindole for schizophrenia
42. Antipsychotic agents and QT changes.]
43. Sudden death in patients receiving clozapine treatment: A preliminary investigation
44. Fatal cardiac event following initiation of risperidone therapy
45. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience
46. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia
47. Risperidone overdose
48. Effect of risperidone on QT interval and QT dispersion in the elderly
49. Antipsychotics and the risk of sudden death
50. Predicting sudden death in the population: The Paris Prospective Study I
51. Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians
52. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland
53. Antipsychotic-induced weight gain: A comprehensive research synthesis
54. Novel antipsychotics: Comparison of weight gain liabilities
55. Novel antipsychotics and new onset diabetes
56. Clozapine-associated elevation in serum triglycerides
57. Novel antipsychotics and severe hyperlipidemia
58. Olanzapine increases weight and serum triglyceride levels
59. The effect of long-term quetiapine monotherapy on weight in patients with schizophrenia
60. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
61. Prevalence of diabetes during extended clozapine and olanzapine treatment
62. Ketoacidosis as a side-effect of clozapine: A case report
63. Olanzapine-induced glucose dysregulation